Pentoxifylline Drug Classification
Pentoxifylline is a methylxanthine derivative classified as a hemorheologic agent. 1
Chemical Classification and Mechanism
Pentoxifylline is chemically a tri-substituted xanthine derivative (1-(5-oxohexyl)-3,7-dimethylxanthine) with a molecular weight of 278.31 and formula C₁₃H₁₈N₄O₃. 1
Unlike theophylline (another methylxanthine), pentoxifylline functions primarily as a hemorheologic agent rather than a bronchodilator, meaning it affects blood viscosity and flow properties. 1
The drug works as a selective phosphodiesterase inhibitor (specifically phosphodiesterase IV), which increases intracellular cAMP levels and subsequently decreases expression of inflammatory cytokines including TNF-α, IL-8, and macrophage inflammatory protein-1α. 2
Pharmacologic Properties
Pentoxifylline exerts multiple complementary effects on blood rheology:
- Decreases blood and plasma viscosity 3
- Increases erythrocyte and leukocyte deformability 3
- Inhibits neutrophil adhesion and activation 3
- Lowers plasma fibrinogen concentrations in some studies 3
- Promotes fibrinolysis and improves blood filterability 4
The drug demonstrates vasodilator, anti-inflammatory, and immunomodulatory properties that extend beyond simple rheologic effects. 5, 4
FDA-Approved Indication
Pentoxifylline is FDA-approved specifically for the treatment of intermittent claudication in patients with chronic occlusive arterial disease of the limbs. 1, 6
Clinical Context and Limitations
According to ACC/AHA guidelines, pentoxifylline is classified as a Class IIb recommendation (may be considered) as second-line alternative therapy to cilostazol for improving walking distance in intermittent claudication, with Level of Evidence A. 3, 7
The clinical effectiveness of pentoxifylline for claudication is marginal and not well established (Level of Evidence C). 3, 7
In a 471-patient randomized controlled trial comparing pentoxifylline with cilostazol and placebo, there was no significant difference in pain-free or maximal walking distance between pentoxifylline and placebo groups, whereas cilostazol improved both outcomes. 3
Parenteral administration of pentoxifylline is not useful for treatment of critical limb ischemia (Class III recommendation). 3